TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05646303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin and psychotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo and psychotherapy
Study: NCT06263426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV D+/R+
Description: Receipt of kidney transplant from a deceased donor with HIV.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV D-/R+
Description: Receipt of kidney transplant from a deceased donor without HIV.
Study: NCT04093739

Intervention type: DEVICE
Intervention: G7 Freedom Constrained Liners
Description: Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
Study: NCT06176300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAR - the SEED Method
Description: The SEED Method is an evidence-based Participatory Action Research (PAR) approach that engages youth and adult stakeholders in collective decision-making and action in supporting PYD opportunities in their communities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAR - the SEED Method
Description: The SEED Method is an evidence-based Participatory Action Research (PAR) approach that engages youth and adult stakeholders in collective decision-making and action in supporting PYD opportunities in their communities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAR-Youth Voices
Description: Youth Voices is a developmentally appropriate and culturally responsive PAR approach designed for African American adolescents. The curriculum relies on frameworks including sociopolitical development (e.g., civic engagement and social justice), racial socialization, and racial identity development. Youth Voices will be implemented in high schools serving the intervention communities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAR-Youth Voices
Description: Youth Voices is a developmentally appropriate and culturally responsive PAR approach designed for African American adolescents. The curriculum relies on frameworks including sociopolitical development (e.g., civic engagement and social justice), racial socialization, and racial identity development. Youth Voices will be implemented in high schools serving the intervention communities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emerging Leaders hospital-based intervention
Description: Emerging Leaders is a violence prevention strategy that provides evidence-based intervention and resources for high-risk youth and their families in the youth's home and community. Emerging Leaders consists of four core components to prevent violence: (1) brief hospital-based violence intervention, (2) 3-months of community case management, (3) an in-home firearm safety counseling program, and (4) an 8-week youth positive development workshop series.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emerging Leaders hospital-based intervention
Description: Emerging Leaders is a violence prevention strategy that provides evidence-based intervention and resources for high-risk youth and their families in the youth's home and community. Emerging Leaders consists of four core components to prevent violence: (1) brief hospital-based violence intervention, (2) 3-months of community case management, (3) an in-home firearm safety counseling program, and (4) an 8-week youth positive development workshop series.
Study: NCT01313104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colposcopy
Description: Undergo colposcopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical Papanicolaou test
Description: Undergo cervical Pap smear

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screening method
Description: Undergo anal Pap smear

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screening method
Description: Undergo high resolution anoscopy
Study: NCT05828238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]SF-DEVD-2
Description: Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FDG
Description: Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
Study: NCT05281601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion.
Study: NCT05772572

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires are completed only once and assess:~* recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~* psychiatric questionnaires for parents and patients on anxiety and depression~* behavior questionnaires for the parents and the patient: assessment of attachment~* questionnaires for the parents and the patient concerning the family context, the quality of life
Study: NCT06380257

Intervention type: OTHER
Intervention: Observational study methods
Description: Neuroimaging, body compostion, laboratory tests and psychiatric interview in study and in control groups.

Intervention type: OTHER
Intervention: Observational study methods
Description: Neuroimaging, body compostion, laboratory tests and psychiatric interview in study and in control groups.
Study: NCT06009692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb Neuro-dynamics (Slider/ Tensioner Technique)
Description: The experimental group will receive neuro-dynamic mobilization techniques along with task oriented training. Slider versus tensioner technique will be applied according to each patient's need. Session time will be 25-30 minutes. Four series of 10 tensioning movements at a rhythm of ∼6s per cycle and 1 min rest between each series will be performed. After each cycle of 10 repetitions, the position will hold for 10s.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy for Upper limb
Description: Conventional treatment will include therapeutic ultrasound for 4 min, TENS for 10 min. Task oriented training will be designed according to patient's functional outcomes. Sessions will be given for 6 days a week, 25-30 minutes per day.
Study: NCT06558461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Chloride
Description: 4ml nebulized three times daily
Study: NCT04283994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey-based Patient/Clinician Jumpstart
Description: The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The Jumpstart takes two forms. One is EHR-based and provides information to the clinician about prior advance care planning documentation derived from the EHR. The other is bi-directional and patient-specific (Survey-based Patient/Clinician Jumpstart Guide). It provides the same information as the EHR-based Clinician Jumpstart Guide but also includes information about patients' self-reported preferences for communication and care as well as primary barriers and facilitators to this communication. The Jumpstart Guides include tips to improve this communication for clinicians, patients and families.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EHR-based Clinician Jumpstart
Description: The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page EHR-based Clinician Jumpstart Guide provides information to the clinician about prior advance care planning documentation derived from the EHR. The EHR-based Clinician Jumpstart Guide includes tips to improve goals-of-care communication.
Study: NCT05420272

Intervention type: BEHAVIORAL
Intervention: Trunk performance and endurance lower extremity biomechanic
Description: Trunk performance and endurance lower extremity biomechanic

Intervention type: BEHAVIORAL
Intervention: Trunk performance and endurance lower extremity biomechanic
Description: Trunk performance and endurance lower extremity biomechanic
Study: NCT06558461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care
Study: NCT04960566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The CBT intervention is based on the theoretical framework that under stress (reflux symptoms) a person makes a rapid cognitive appraisal of the potential threat (automatic thoughts), leading to both emotional and physical responses in the body, thereby reacting behaviorally (avoidance, increased HCU) in an attempt to mitigate unpleasantness. CBT is a collaborative, present-focused treatment that utilizes a skills-based approach with home practice exercises. CBT targets automatic thoughts and appraisals of threat via education, self-monitoring of stressors and symptoms, and strategies to reframe problematic thinking patterns to more adaptive ones. Resonance frequency breathing (RFB) is achieved when a person breathes at a pace, typically 4 to 6 breaths per minute, that engages the body's baroreflex to modulate arousal. Prior research demonstrates 4 to 6 weeks of RFB training is sufficient to significantly increase baseline HRV with enduring effects for up to 6 months.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-SOC Lifestyle Coaching
Description: Sham-SOC Lifestyle Coaching
Study: NCT05940844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OB-002
Description: The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OB-002
Description: The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OB-002
Description: The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OB-002
Description: The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
Study: NCT05965817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101 op top of ICG
Description: SGM-101 op top of ICG
Study: NCT05845957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Education Group
Description: Providing training on safe pediatric intravenous drug administration with digital storytelling method
Study: NCT05791734

Intervention type: OTHER
Intervention: assessing preoperative skin cleanliness
Description: 2 skin swabs on surgical incision sites and direct skin visual observation by a nurse
Study: NCT06283121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioTTT001 intraperitoneal infusion
Description: Monotherapy lead-in phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3; Combination therapy phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3, 3 weeks per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX regimen
Description: Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
Study: NCT05527158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yi Jin Jing exercise
Description: Yi Jin Jing of The General Administration of Sport of China, which consists of twelve operational processes as the standard intervention
Study: NCT05664607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: for excise, nutrition consultant, nutrition supplement and psychologic intervention.
Description: for excise, nutrition consultant, nutrition supplement and psychologic intervention.
Study: NCT06550128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHB-137 injection
Description: AHB-137 injection will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AHB-137 injection
Description: AHB-137 injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study: NCT06160167

Intervention type: DRUG
Intervention: IMiD treatment
Description: Participants with MM treated with IMiDs

Intervention type: DRUG
Intervention: No IMiD treatment
Description: Participants with MM not treated with IMiDs

Intervention type: DRUG
Intervention: Systemic therapy
Description: Participants with MM treated with systemic therapy
Study: NCT06637124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy Device
Description: Blood Flow Restriction (BFR) therapy involves units use standardized cuffs of varying widths and lengths which are physically attached to the devices and provide the capability of precisely controlling the amount of pressure applied to each limb during exercise or at rest.~We will be using Smart Cuffs® 4.0 which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it will calculate and set the optimal pressure for each participant's limb. There is no need for an external doppler probe or hand pump. Made in the USA, SmartCuffs® are registered with the FDA as a Class 1 Medical Device.~Blood flow restriction therapy is commonly paired with resistive training, so this study will explore the effect of blood flow restriction at rest for patients with osteoarthritis at different restriction levels (50% for first group and 70% for second group).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy Device
Description: Blood Flow Restriction (BFR) therapy involves units use standardized cuffs of varying widths and lengths which are physically attached to the devices and provide the capability of precisely controlling the amount of pressure applied to each limb during exercise or at rest.~We will be using Smart Cuffs® 4.0 which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it will calculate and set the optimal pressure for each participant's limb. There is no need for an external doppler probe or hand pump. Made in the USA, SmartCuffs® are registered with the FDA as a Class 1 Medical Device.~Blood flow restriction therapy is commonly paired with resistive training, so this study will explore the effect of blood flow restriction at rest for patients with osteoarthritis at different restriction levels (50% for first group and 70% for second group).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.
Description: Patients assigned to group will receive strengthening of the lower limb musculature through moderate intensity resistance training (60% of 1RM) using a 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.
Study: NCT06645223

Intervention type: DRUG
Intervention: No Interventions
Description: no interventions

Intervention type: DRUG
Intervention: No Interventions
Description: no interventions
Study: NCT06639009

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 940nm diode laser photobiomodulation
Description: The surgical handpiece (diameter 0.6cm) will be used without the fibre optic tips in defocused mode and head sanitized before therapy.~Peak Power : 0.3Watts Power density: 1 Watt/cm2 Fluence: 4J/cm2 per cycle Spot size : 0.28cm2 Distance : 2mm from surface Mode: Continuous, Non- contact mode, circular motion, overlapping, in clockwise concentric manner with laser handpiece perpendicular to surface Duration of cycle : 25 seconds with interval of 30 seconds alternating with other side Cycles per sitting: Four for each side Four Sittings: Day 0,3, 7, and 15 Area of intervention: Bilateral buccal mucosa and masseter muscle Total treatment time per day: 430 seconds/ approx 7 minutes Total treatment time for 4 sittings: approx 28 minutes
Study: NCT05252624

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet manufactured to mimic henagliflozin 5 mg tablet
Study: NCT04757246

Intervention type: OTHER
Group type: OTHER
Intervention: MouthLab Device
Description: Use of MouthLab system

Intervention type: OTHER
Group type: OTHER
Intervention: MouthLab Device
Description: Use of MouthLab system

Intervention type: OTHER
Group type: OTHER
Intervention: MouthLab Device
Description: Use of MouthLab system
Study: NCT05940844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OB-002
Description: The patients will be dosed once weekly (Days 1, 8, 15 and 22) over a 4-week treatment cycle with a 28 day dose-limiting toxicity (DLT) observation period.
Study: NCT06462885

Intervention type: BEHAVIORAL
Intervention: home support, hiving alone
Description: Home support: living alone

Intervention type: BEHAVIORAL
Intervention: home support, living with others
Description: Home support: living with others
Study: NCT05252624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Henagliflozin 5Mg Tab
Description: Single oral tablet
Study: NCT05002309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Therapy
Description: 20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly homework will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Description: The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
Study: NCT06125405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
Study: NCT06073067

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GRID therapy
Description: GRID therapy delivers a high dose of radiation to small areas of tumor interleaved with areas that intentionally receive a low dose
Study: NCT05031897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Undergo DLI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Undergo DLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration/ biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration/ biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo diagnostic imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo diagnostic imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection